Dr. Michael Wangler

Houston, Texas

Baylor College of Medicine

A metabolomics resource for peroxisomal disorders and related conditions such as D-bifunctional protein deficiency and Rhizomelic chondrodysplasia punctata (RCDP) is being created.

Learn more ->

Di Wu

Rockville, Maryland

The National Center for Advancing Translational Sciences (NCATS) at the National Institutes of Health (NIH) has hired Di Wu, a postdoctoral fellow to work on drug screening projects. GFPD is one of only 10 patient advocacy groups/nonprofit public charities in the world to be accepted into this program at NCATS

Dr. Joseph Hacia

Los Angeles, California

University of Southern California

Dr. Hacia has spearheaded a multi-year project developing research resources for neurodegeneration and vision loss in peroxisomal disorders. Currently, a rat with a central nervous system defect is being developed with Dr. Hacia’s collaborator, Dr. Quilong Ying. Development of this rat will allow treatments for the brain to be tested in an animal model prior to moving to human clinical testing.

Learn more ->

Dr. Nancy Braverman

Montreal, Quebec, Canada

McGill University

A PEX 1 mouse model is being used to (1) optimize our retinal gene therapy projects and (2) test candidate drugs for potential therapies at McGill University in Montreal, Quebec, Canada.

Learn more ->